Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

News Conference News AHA 2024

Novel AI-Based, Noninvasive Sensor Can Accurately Measure PCWP in HFrEF

Yael L. Maxwell

November 25, 2024

News Conference News AHA 2024

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

L.A. McKeown

November 22, 2024

News Conference News AHA 2024

Infections No More Likely With Reconditioned Versus New Pacemakers

Yael L. Maxwell

November 22, 2024

News Conference News AHA 2024

Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN

Caitlin E. Cox

November 22, 2024

News Conference News AHA 2024

Two Trials Provide Insights Into Catheter Ablation Options for Persistent AF

Todd Neale

November 21, 2024

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Caitlin E. Cox

November 21, 2024

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

News Conference News AHA 2024

Talking Sex: CVD Patients Want to Hear More From Clinicians

Caitlin E. Cox

November 20, 2024

News Conference News AHA 2024

AI Poised to Change the Landscape of Echocardiography

Yael L. Maxwell

November 19, 2024

News Conference News AHA 2024

Extreme Heat Seems to Spark More Atrial Arrhythmias in IED Patients

Todd Neale

November 19, 2024

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

Presentation AHA 2024

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Presenter: Marcely Gimenes Bonatto

November 18, 2024

Presentation AHA 2024

Randomized Study Comparing PK/PD Properties of a Novel Intranasal Formulation of Bumetanide to Oral and IV Formulations

Presenter: Daniel Bensimhon

November 18, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

Todd Neale

November 18, 2024

News Conference News AHA 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

Caitlin E. Cox

November 18, 2024

News Conference News AHA 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

Shelley Wood

November 18, 2024

News Conference News AHA 2024

Nasal Bumetanide Safe, Effective in Healthy Adults

Yael L. Maxwell

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

Advertisement

Novel AI-Based, Noninvasive Sensor Can Accurately Measure PCWP in HFrEF

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

Infections No More Likely With Reconditioned Versus New Pacemakers

Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN

Two Trials Provide Insights Into Catheter Ablation Options for Persistent AF

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Talking Sex: CVD Patients Want to Hear More From Clinicians

AI Poised to Change the Landscape of Echocardiography

Extreme Heat Seems to Spark More Atrial Arrhythmias in IED Patients

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Randomized Study Comparing PK/PD Properties of a Novel Intranasal Formulation of Bumetanide to Oral and IV Formulations

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

Nasal Bumetanide Safe, Effective in Healthy Adults

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content